Given the high prevalence of inhA promoter mutations among patients with drug-resistant TB in certain settings, providing specific gene mutations when reporting LPA results may allow clinicians to adjust a patient’s regimen and maximize its effectiveness. This evidence concerns the gene INHA and tuberculosis.